DualityBio – Talk Bio

BioNTech and DualityBio Achieve Phase 3 Success with ADC Therapy for HER2-Positive Breast Cancer, Advancing Oncology Pipeline

3 days ago talkbio0Tagged Antibody-Drug Conjugates, BioNTech, DualityBio, HER2-positive carcinoma of breast, Market, Oncology Pipeline, pamirtecan, Phase 3 trial, Progression-Free Survival, trastuzumab

BioNTech; DualityBio; antibody-drug conjugate (ADC); HER2-positive breast cancer; trastuzumab pamirtecan; BNT323/DB-1303; phase 3 trial; progression-free survival; oncology pipeline; ADC market

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

5 months ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.

GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC

9 months ago talkbio0Tagged ADC, biotech, DualityBio, pharmaceutical partnerships, Preclinical, SmithKline Beecham, therapeutic autologous dendritic cells

GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships